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ABSTRACT 
 
Background: Numerous research studies have attempted to determine the causes of male infertility with the objective of 
developing therapeutic approaches to effectively improve various semen parameters. Aim: The presented intervention is a 
quantitative approach that categorically assesses the therapeutic advantage of oral GSH (glutathione) administration on various 
semen parameters including sperm concentration, morphology, and motility in infertile males. Methods: The prospective 
placebo-controlled study included 101 infertile adult males through random selection between the timeframe of Jan 2017 to 
Mar 2018. We selected total 101 subjects who did not experience any chronic disease of the reproductive system and exhibited 
normal female factor. GSH oral therapy was administered between 0 to 6 months, 51 patients received GSH therapy and 50 
patients received placebo in the form of glucose sachets. At the time of 0, 3 and 6 months, the blood and semen samples were 
taken for analyses for treatment and placebo groups. Results: The findings recorded at 0 weeks, 3 months, and 6 months 
interval revealed a significant p-value. At 0 week, there wasn’t any  statistical significance for the results while at 3 months, 
GSH value was 4.55 mg/dl for GSH group therapy in comparison for 1.55 mg/dl for placebo group which was statistically 
significant. Conclusion: The study findings revealed a strong positive relationship between oral GSH therapy and the selected 
sperm parameters.  
Key words: Oral GSH, male infertility, glutathione, sperm concentration, sperm morphology, sperm  motility. 
 
ale infertility is associated with the 
psychological trauma, specifically for married 
couples and poses a serious threat to their 
mental health and wellness to a considerable extent. 
Oxidative stress is one of the major causes of male 
infertility and substantially impacts the equilibrium 
between protective antioxidants and reactive oxygen 
species (ROS ). Several antioxidants antagonize the 
adverse impact of reactive oxygen species while 
facilitating the cellular repair processes. Glutathione 
(GSH) effectively antagonizes the level of reactive oxygen 
species while effectively inducing the antioxidant defense 
mechanisms of the human body [1].  
Antioxidant property of GSH also helps in controlling 
the level of free radicals in the context of stabilizing 
reproductive microenvironment. GSH, in this manner, is 
believed to improve the reproductive capacity of adult 
males. The study finding of Yao DF et al  2016, reveals the 
intracellular antioxidant action of GSH that effectively 
improves sperm morphology and motility in adult males 
[2]. The antioxidant genes including glutathione S-
transferase (GST) and glutathione peroxidase (GPX) plays 
a pivotal role in normalizing the sperm function and 
spermatogenesis in males [3]. However, disruption of these 
genes substantially increases the risk of subfertility, 
oligozoospermia, oligoasthenoteratozoospermia, and 
reduced sperm quality [3]. 
The adverse impact of functional polymorphisms and 
reactive oxygen species on GST and GPX leads to the 
establishment of infertility pattern in the affected males. 
M 
Mohammed S Aulkumait                                                                                          Male Infertility & Glutathione 
 
Vol 4| Issue 1| Jan-Mar 2019                                                                                        Eastern J Medical Sciences 25 
GSH substantially improves mitochondrial DNA function 
and proves to be a co-factor for numerous vitamins and 
enzymes that effectively explores the impact of glutathione 
oral therapy on the sperm motility, morphology, and 
concentration in adult males [4]. Many previous studies 
have revealed the potential of use of GSH on sperm 
motility & morphology [5-9]. In fact, evidence-based 
findings reveal research gaps in relation to GSH therapy 
and enhancement of semen attributes in adult males. 
 Accordingly, the present study evaluates the 
effectiveness of GSH therapy in elevating the overall 
semen functionality and sperm count. It explores the 
potential of orally administered GSH in terms of 
improving the sperm motility, concentration, and 
morphology in adult males. 
METHODS 
The present prospective randomized placebo-controlled 
study was conducted in Saladin province of Samarra city 
(Iraq) between Jan 2017 to Mar 2018. The study deployed 
51 infertile male subjects who exhibited normal female 
factor for the administration of oral glutathione (250mg 
sachets), for tenure of 6-months. However, 50 infertile 
males received the placebo treatment. The patients affected 
with chronic diseases including mumps, hydrocele, 
neoplasm, varicocele, trauma from prolonged riding, 
neoplasm, varicocele, vas deferens obstruction, 
hypospadias, and genital tract infection, were summarily 
excluded from the study.  Furthermore, infertile males, 
who had recently received infertility treatment were also 
not allowed to participate in the research study. The male 
participants between the age group of 35-40 years, were 
included in the research intervention.   
Informed consent was obtained from the entire study 
subjects while categorically explaining them the 
interventions, objectives, and outcomes. Data collection 
from study participants was undertaken after the 
acquisition of the informed consent. Oral administration of 
GSH sachets to the study participants (i.e. the treatment 
group only) was undertaken for a period of 6-months. The 
placebo group did not receive the GSH treatment for the 
same time. However, placebo group participants (who 
received glucose sachets), remained unaware of the 
treatment intervention because of the single-blinded nature 
of the study intervention. 
Blood and semen samples were obtained from the 
treatment and placebo groups at 0 weeks, 3 months, and 6 
months period. Blood sampling was performed with the 
core objective of detecting the GSH concentration. 
Addition of a precipitating solution and centrifugation 
were performed in the context of evaluating the seminal 
plasma GSH by utilizing the Ellman method. Data 
collection from study participants was undertaken and the 
participants shared the significant information related to 
their social habits, marriage duration, occupation, and age 
during the interview session.   
Data analysis was done through SPSS 15.0 in the 
windows interface. Mann Whitney U-test and unpaired t-
test were systematically utilized for assessing the data 
significance for P value<0.05. The genital organs of the 
entire study participants were examined to evaluate their 
size of vas deferens, epididymis, and testes while 
concomitantly assessing/ruling-out the presence of a 
varicocele.  
RESULTS 
Total 101 patients were included in this study and out 
of them 51 patients received GSH treatment. Table 1 
present the outcomes obtained at 0 weeks, 3 months, and 6 
months of oral GSH and placebo treatment administration.  
Table – 1 (Participants’ age and semen parameters 
recorded at 0-week) 
Domains Placebo 
group 
(n=50) 
GSH group  
( n=51) 
P 
value 
Age (years) 35.82±4.92 35.21±5.18 >   0.05 
Semen 
Volume (ml) 
2.21±0.92 2.25±0.85 >   0.05 
Semen 
concentration 
(million) 
51.5±8.2 50.2±8.1 > 0.05 
% of motility 27.5±2.5 27.0±2.6 >   0.05 
Morphology 9.5±3.1 9.8±3.2 >  0.05 
No significant difference regarding the semen 
parameters was recorded between the two groups at the 
beginning of the study intervention.  
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Table – 2 (Seminal plasma GSH levels & GSH levels in blood) 
GSH Level in Seminal Plasma (mg/dl) 
6 months 3 months 0 weeks P value 
Placebo n=50 GSH group 
n=51 
Placebo n=50 GSH group 
n=51 
Placebo n=50 GSH group 
n=51 
 
1.52 (0.27-7.02) 4.58 (2.55-7.25) 1.55 (0.26-7.04) 4.55 (2.58-7.20) 1.58 (0.26-7.02) 1.52 (0.25-6.92) <0.001 
GSH levels in the blood 
14.78 (0.80-29.2) 15.25 (2.28-26.2) 14.8 (0.89-29.1) 15.2 (2.26-25.4) 14.8 (0.86-29.20) 14.5 (0.85-28.2) >0.05 
The outcomes reveal serum plasma GSH elevation in 
the treatment group at 3
rd
 and 6
th
 months of the oral GSH 
therapy. P-value was recorded to be less than 0.001 during 
this tenure. The outcomes at 0 weeks, 3 months, and 6 
months did not reveal any significant difference between 
blood GSH levels of the treatment and placebo groups 
(Table 2).  
Table – 3 (Semen parameters in response to the oral 
GSH/placebo therapy) 
The following outcomes regarding the semen 
parameters were recorded after therapeutic administration 
of oral GSH to the treatment group: The significant p-
value of 0.01 for the sperm motility was recorded at 3rd 
and 6th months of treatment for the GSH group; The 
significant p-value for the sperm morphology was recorded 
as 0.03 for the GSH group at 3rd and 6th months of oral 
GSH treatment; The significant p-value of 0.01 for the 
sperm concentration was recorded for the GSH group at 
3rd and 6th months of oral GSH administration (Table 3).  
The study outcomes revealed oral GSH therapy as an 
effective treatment for improving the pattern of sperm  
 
concentration, morphology, and motility of the selected 
subjects.  
DISCUSSION 
Male infertility is a direct outcome of inconsistencies 
in sperm morphology, motility, and concentration. 
Immature oocytes significantly lead to premature 
chromosome condensation across the sperm cell lines. The 
study by Ahmadi S et al. 2016 advocates the need for 
semen analysis in the context of evaluating motility, 
morphology, and concentration of the human sperms [5]. 
The reduction in antioxidant semen capacity substantially 
increases the risk of sperm abnormalities including 
oligoasthenoteratozoospermia, teratozoospermia (i.e. 
disfigured sperm morphology), asthenospermia (i.e. 
decreased sperm motility), and oligozoospermia (i.e. 
decreased sperm concentration) [5]. Since glutathione is 
one of the several antioxidants in human serum, its 
elevated concentration is believed to improve sperm 
physiology and concentration in adult males.  
The study by Majzoub A et al. 2017 reveals the 
potential of GSH to effectively protect the human sperms 
from the adverse impact of lipid peroxidation [6]. This 
protective effect of GSH improves the sperm motility and 
viability to a considerable extent. Glutathione reductase 
extends protective effect over the sperm membrane 
attributes and tail-beat frequency. Some studies reveal the 
poor absorbance of GSH across the intestinal tract that 
reciprocally impacts its bioavailability and therapeutic 
outcomes [6]. Research intervention by Lombardo F et al.  
2011 [7], reveals the limited evidence regarding the 
beneficial outcomes of antioxidant therapies in male 
affected with infertility. In-vitro assessment reveals the 
potential of GSH in terms of safeguarding the ROS-based 
Parameters 6 months 3 months P 
value 
 Placebo 
n=50 
GSH 
n=5
1 
Placebo 
n=50 
GSH 
n=51 
% of motility 3.5 38.4 3.5 38.2  0.01 
% of 
morphology 
4.6 27.2 4.5 26 0.03 
% of sperm 
concentration 
1.6 24.2 1.8 24 0.01 
Mohammed S Aulkumait                                                                                          Male Infertility & Glutathione 
 
Vol 4| Issue 1| Jan-Mar 2019                                                                                        Eastern J Medical Sciences 27 
DNA loss in adult males. Similarly, the pre-clinical study 
by Tuncer et al. 2010 [8] reveals limited spermatic DNA 
damage under the impact of GSH administration. Study 
outcomes of Majzoub A et al. 2018 evidently describe the 
beneficial outcomes of several antioxidants on the male 
fertility pattern [9]. However, prospective studies require 
execution on a wider scale in the context of determining an 
optimal antioxidant therapy to facilitate the safe and 
effective treatment of male fertility in clinics and hospital 
settings 
The study outcomes by Meybodi AH et al. 2012, [10] 
reveal the capacity of GSH intervention to reduce the 
oxidative stress of the sperm cells that resultantly improves 
their motility and increases the scope of fertilization. The 
outcomes of the presented study effectively concord with 
the evidence-based findings that reveal the protective 
effect of GSH on sperm motility and maturation. However, 
the presented study does not reveal the GSH mechanism 
that safeguards seminal plasma and sperm from oxidative 
stress. Previous studies also suggested about the higher 
risk of oxidative stress-based disruption of sperm cell line 
in the infertile males who reportedly undergo glutathione 
transferase enzyme mutation [10]. Numerous research 
studies reveal both positive and negative correlations (i.e. 
controversial findings) between the GPX activity in 
seminal plasma and sperm motility/quality pattern [11]. 
These outcomes substantiate the requirement of assessing 
the seminal plasma in the context of determining probable 
mutations in the antioxidative defense enzymes across the 
sperm cell lines. This diagnostic intervention is required to 
identify the defects or mutations in protein expressions that 
directly result in male infertility. Accordingly, researchers 
can optimize the oral GSH dosage to effectively overcome 
the inconsistencies in antioxidative defense enzyme for 
improving the overall semen quality. The presented study 
outcomes prove to be the ladder in this direction that the 
researchers need to utilize for evaluating numerous semen 
parameters on a wider scale to effectively generalize the 
utilization of GSH therapy for the infertile males.  
The assessment by Agarwal et al. 2014 [12] reveals the 
potential of the excess residual cytoplasm of the 
deteriorated immature spermatozoa to disrupt the sperm 
morphology and motility. The excess residual cytoplasm 
of the degraded spermatozoa utilizes the hexose-
monophosphate shunt to effectively induce the NADPH 
system. This resultantly hinders the ROS equilibrium and 
increases the oxidative stress that results in degradation of 
sperm quality and fertilization capacity of the adult males 
[12]. Our study reveals the positive influence of oral GSH 
therapy on sperm morphology. However, prospective 
research studies require execution with the objective of 
understanding the impact of oral GSH therapy on NADPH 
induction pattern across the deteriorated spermatozoa. This 
will effectively help in determining the biochemical 
pathways interfered by the oral GSH therapy in the 
infertile males.  
The analysis by Hsieh et al. 2006 [13] reveals an 
insignificant correlation between seminal quality and GPX 
activity. Study outcomes advocate the need for assessing 
seminal MDA (malondialdehyde) concentration to identify 
the extent of degradation in sperm motility and 
concentration in the infertile males. This study effectively 
reveals a positive correlation between the sperm 
concentration and oral GSH administration. However, the 
study does not identify the mechanism of GSH interaction 
with seminal malondialdehyde in the study subjects. The 
assessment by Yesteet al 2013 [14] reveals the 
constructive influence of reduced-glutathione on the 
nucleoprotein pattern of the deteriorated and 
underdeveloped spermatozoa. The findings, therefore, 
indicate the need for GSH administration for the 
enhancement of sperm viability in the infertile males. Our 
study indicates the linear improvement in semen 
parameters following the GSH administration. However, 
greater analysis of the associated mechanisms is required 
to authenticate and generalize the positive correlation 
between oral GSH therapy and extended semen parameters 
and biomolecular pathways.  
The study limitations are based on the restricted sample 
size and absence of a thorough analysis of biochemical 
interactions of GSH with the deteriorated sperm cells of 
the selected males. The researchers need to replicate the 
study on a wider scale while considering the oral 
absorption and bioavailability of the oral GSH in the male 
population. The prospective assessment of GSH effects on 
various semen parameters including MDA concentration, 
NADPH system, glutathione peroxidase activity, sperm 
nucleus structure, and GSHr/GSSG concentration is 
necessarily required to effectively optimize oral GSH 
therapy for the infertile males. Furthermore, GSH impact 
on ROS and oxidative stress requires further exploration 
Mohammed S Aulkumait                                                                                          Male Infertility & Glutathione 
 
Vol 4| Issue 1| Jan-Mar 2019                                                                                        Eastern J Medical Sciences 28 
while evaluating the associated biomolecular pathways. 
The researchers also need to investigate the scope of co-
administering other antioxidants like carnitine, selenium, 
and vitamin B complex with oral GSH therapy to 
minimize the prevalence of male infertility in the selected 
population. 
CONCLUSION 
The present study effectively evaluates the effectiveness of 
oral GSH therapy on semen parameters including sperm 
motility, morphology, and concentration. The findings 
categorically reveal the therapeutic advantage of oral GSH 
intervention in terms of improving the selected semen 
parameters in the infertile males.  
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